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drug treatment, occupational advancement, current work status, and direct cost was 
detected in univariate analyses. CONCLUSIONS: To our best knowledge this is the 
ﬁrst observational study on the burden of GTS in Germany. With annual total costs 
of about a12,500, GTS places a notable ﬁnancial burden on society. HrQoL is 
 considerably reduced in patients with GTS. While tic treatment is important, co-
 morbidities such as depression should be regarded more seriously.
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OBJECTIVES: To assess change in health-related quality of life (HRQoL) over time 
in MS patients treated with natalizumab in a “usual care setting” in the United States 
(US). METHODS: MS patients starting natalizumab were invited to participate in a 
1-year longitudinal health outcomes study assessing their experiences with natali-
zumab. MS patients complete self-reported assessments prior to natalizumab initiation 
and after the 3rd, 6th and 12th natalizumab infusions. The current analysis reports the 
change in general HRQoL assessments using the SF-12v2 from baseline through the 
6th natalizumab infusion. Physical and Mental Component Summary (PCS and MCS, 
respectively) scores were computed at each assessment. PCS and MCS scores range 
from 0 to 100, with higher scores indicating better HRQoL. The a-priori study 
hypothesis was that patient-reported HRQoL improves over time with longer duration 
of natalizumab treatment. Statistical regression models were used to evaluate changes 
in HRQoL over time after controlling for the number of natalizumab infusions, age, 
years since MS diagnosis, baseline disease disability and functional status, comorbidity 
burden, and number of drugs used prior to natalizumab. RESULTS: Data for 296 
patients were analyzed. The mean age was 47 / 11 years and the majority of patients 
were female (78%). The mean number of years since MS diagnosis was 11 / 9 years. 
After controlling for covariates, a statistically signiﬁcant increase (improvement) in 
PCS scores (BL 34 / 11, 3rd 36 / 12 and 6th 36 / 11; p  0.0001) and MCS 
scores (BL 43 / 12, 3rd 47 / 11 and 6th 48 / 11; p  0.0001) was observed from 
baseline through the 6th infusion. CONCLUSIONS: Patients reported signiﬁcant 
improvements in both physical and mental aspects of HRQoL over 6 months of treat-
ment, suggesting an improved effect of natalizumab over time. These results document 
the improvement in HRQoL of MS patients receiving natalizumab in the usual care 
setting and are consistent with clinical study ﬁndings.
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OBJECTIVES: Reports from clinical trials suggest that physical activity (PA) can be 
beneﬁcial for multiple sclerosis (MS) patients. However, participation in PA was found 
to be low in MS patients with substantial physical disability. We assessed levels of PA 
and their interaction with depression and health related quality of life (HRQoL) in 
early-stage MS patients. METHODS: The BEGIN study (Betaferon® treatment and 
Exercise data Gathering IN early MS) is an international prospective observational 
study of early-stage MS patients, including clinically isolated syndrome suggestive of 
MS, treated with Betaferon®. PA levels were assessed by the International Physical 
Activity Questionnaire (IPAQ) and a pedometer, and depression using the Center for 
Epidemiological Studies Depression Scale (CES-D), and HRQoL with the EuroQoL 5 
dimension (EQ-5D) utility scale and Visual Analogue Scale (VAS) score. RESULTS: 
PA data were collected from 609 patients (68.0% women) in 16 countries in Europe, 
Asia, Australia and Latin America. Mean age was 36.3 years (SD  9.9). The median 
MET-minutes/week derived from IPAQ at baseline was 3349 (SD  3616), with 
25.2%, 32.5% and 42.6% of patients categorized as low, moderate and high PA level, 
respectively. The median steps per day were 6,728 (IQR  4,942). A negative Spear-
man’s rank correlation was found between the steps per day and depressive symptoms 
(p  0.01).Mean depression scores decreased monotonically in higher IPAQ categories. 
EQ-5D utility and VAS scores were on average 0.7 (SD  0.2) and 71.7 (SD  19.5), 
respectively. The steps per day showed to be positively correlated with both VAS 
(p  0.01) and utility (p  0.01) outcomes. CONCLUSIONS: PA in early-stage MS 
patients was found to be positively associated with HRQoL. Adding the results of the 
longitudinal data after two years of follow-up may lead to further insights regarding 
the role of PA in early-stage MS patients and its relation to HRQoL.
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OBJECTIVES: To assess patient-reported treatment satisfaction with natalizumab in 
MS patients in the United States (US). METHODS: MS patients initiating natalizumab 
were invited to participate in a longitudinal study. Patients complete self-reported 
assessments prior to natalizumab initiation and then after the 3rd, 6th and 12th natali-
zumab infusions. As part of the baseline (BL) assessment, patients reported their sat-
isfaction with MS drugs used prior to natalizumab initiation. For the follow-up 
assessments, patients reported their satisfaction with natalizumab treatment. Patient 
self-reported measures included satisfaction with treatment effectiveness, convenience 
of use, and global treatment satisfaction scales from the Treatment Satisfaction Ques-
tionnaire. Each scale consists of 3 items, with responses measured on a 7-point Likert 
Scale ranging from 1 (low) to 7 (high). Individual item responses are added and scores 
are transformed to a 0 to 100 scale with higher scores indicating higher satisfaction. 
This analysis evaluates the change in satisfaction from baseline through the 6th natali-
zumab infusion after controlling for number of natalizumab infusions, age, years since 
MS diagnosis, baseline disease disability and functional status, comorbidity burden, 
and number of MS drugs used prior to natalizumab. RESULTS: Data from 296 
patients indicated that 78% are female, the mean age is 47 o 11 years and the mean 
time since MS diagnosis is 11 o 9 years. Almost all (97%) patients used at least one 
other MS drug before natalizumab. After controlling for covariates, signiﬁcant 
increases in effectiveness (BL 44.22 o 8.62, 3rd 61.91 o 6.87 and 6th 69.48 o 4.96, p 
 0.0001), convenience (BL 60.80 o 6.27, 3rd 79.18 o 3.25 and 6th 79.69 o 0.42, p  
0.0001), and global satisfaction (BL 62.46 o 3.92, 3rd 75.36 o 3.92 and 6th 76.51 o 
3.92, p  0.0001) were observed. CONCLUSIONS: Patients’ satisfaction with natali-
zumab increased with increasing treatment duration. Patients reported higher levels 
of satisfaction with treatment effectiveness, convenience of use, and global satisfaction 
while receiving natalizumab compared to their satisfaction levels with MS drugs 
received before initiating natalizumab.
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OBJECTIVES: Estimating the minimal important difference (MID) of patient reported 
outcome (PRO) measures is important to guide interpretations of scores and for 
assessing treatment efﬁcacy in clinical trials and studies. The current study was 
designed to estimate the MID of newly developed PROs for Multiple Sclerosis (MS); 
The Patient Reported Indices for Multiple Sclerosis (PRIMUS; which includes Activity 
and Quality of Life (QoL) scales) and Unidimensional Fatigue Impact Scale (U-FIS). 
The measures have been shown previously to be unidimensional, valid and reliable. 
METHODS: Data were taken from the TRANSFORMS study, a multi-country phase 
III study evaluating the safety and efﬁcacy of oral ﬁngolimod compared to IFNB-1a 
i.m. in relapsing-remitting MS patients. PRO assessments were completed at baseline, 
6 and 12 months. Measures included the PRIMUS-Activities (scored 0–30), PRIMUS-
QoL (scored 0–22), U-FIS (scored 0–66) and EQ-5D. For PRIMUS and U-FIS scales, 
a high score indicates more severe impact. Both anchor (published EQ-5D MID values) 
and distribution (0.2 and 0.5 effect sizes, standard error of measurement) based 
approaches were employed. Anchor-based MID values were assessed both for indi-
viduals who improved or deteriorated according to EQ-5D MID values. Triangulation 
of results provided the ﬁnal PRIMUS and U-FIS MID estimates. RESULTS: Trial 
sample: n  1292, 67.3% female, mean age 36.2 (SD  8.5), mean MS duration 7.4 
years (SD  6.2). Anchor and distribution based MID’s ranged from 0.9–2.9 (PRIMUS 
QoL), 0.7–2.3 (PRIMUS Activities) and 2.4–7.3 (U-FIS). Triangulation resulted in the 
following MID values; PRIMUS Activities 1.5 for individuals improving or deteriorat-
ing; PRIMUS QoL 1.5 for individuals improving or deteriorating and U-FIS 4.5 for 
those improving and 5.0 for those deteriorating. CONCLUSIONS: The analyses 
provide preliminary information on the interpretation of scores on the scales. The 
MID values will aid the assessment of treatment efﬁcacy in clinical trials and 
studies.
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OBJECTIVES: To measure the association of health-related quality of life (HRQoL) 
and pre-baseline relapse among multiple sclerosis (MS) patients in a real-world obser-
vational study. METHODS: The Real-World Betaseron Outcomes Study (ROBUST) 
is a 12-month, US prospective, observational, open-label, single-arm, multi-center 
outcomes study of interferon beta-1b given every other day for MS. Patient outcomes, 
including relapse history, were reported independently by both patients and physicians 
via a web-based data capture tool. A total of 226 patients were registered across 52 
sites, and 193 completed the baseline survey. Analysis of variance methods were used 
to measure the association of SF-12 Health Survey (SF-12) scores and pre-baseline 
relapse descriptors (relapse status, frequency, severity of typical and worst relapse). 
SF-12 results were summarized by Physical Component Score (PCS-12) and Mental 
Component Score (MCS-12). RESULTS: Both physical and mental scores were lower 
among patients reporting to be in relapse at baseline (N  78) than among those 
reporting to be relapse-free at baseline (N  115); however, the difference was statisti-
cally signiﬁcant only on the MCS-12 (43.9 vs. 40.5; p  0.045). Reduction of both 
PCS-12 and MCS-12 were strongly associated with increasing frequency of patient 
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reported relapses (p  0.001 for both); there was no association between SF-12 and 
physician reported frequency of relapses. PCS-12 was also signiﬁcantly associated with 
physician-assessed severity of relapse (p  0.002 for typical; p  0.001 for worst 
relapse, respectively) as well as patient-assessed severity of relapse (p  0.001 for 
typical; p  0.001 for worst relapse). Mental scores, however, were not signiﬁcantly 
associated with physician- or patient-reported relapse severity. CONCLUSIONS: As 
a generic HRQoL tool, the SF-12 was associated with relapses in an MS population. 
In patient-reported, as opposed to neurologist-reported, frequency of relapses was 
associated with a lower HRQoL. Patient- and neurologist-assessed severity of relapses 
was linked to a lower physical QoL. These observations suggest that relapses, both in 
quantity and severity, have a negative impact on HRQoL as measured by the SF-12.
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OBJECTIVES: The aim of this study was to evaluate the impact of symptoms related 
to Parkinson’s disease (PD) on health-related quality of life. METHODS: Observa-
tional, multicenter, cross sectional study in patients with PD, older than 18, who had 
received PD medication for at least 1 year before inclusion. The following assessments 
were applied: Hoehn and Yahr staging of PD (HY), SCOPA-Motor (SC-M), Non-
Motor Symptoms Questionnaire (NMSQ), QUICK Questionnaire (QQ, for detection 
of wearing-off, WO) and PDQ-39 to evaluate quality of life in PD patients. RESULTS: 
1.173 evaluable patients were included, 58.6% were males, mean age (SD) was 71.4 
(8.6) years and most of them were in HY stage 2 or 3 (70.3%). According to SC-M, 
94.5% patients presented rigidity, 93.1% rapid alternating hand movements and 
84.5% alteration of walking. Mean score of SC-M and NMSQ was 19.3 (12.6) and 
9.7 (6.1) points, respectively. Regarding the quality of life evaluated using the PDQ-39 
questionnaire, global score was 26.6 (18.6) points. Spearman correlation coefﬁcients 
between PDQ-39 and the other measures were: HY, 0.55; SC-M, 0.76; NMSQ, 0.73; 
and QQ, 0.67. 59.2% patients presented WO according to QQ. Quality of life was 
better for patients without WO: PDQ-39 score 20.0 (17.4) vs 30.8 (18.2) points in 
patients with WO (p  0.0001). CONCLUSIONS: The results of this study suggest 
that Parkinson’s disease patients present a combination of motor and no-motor 
symptoms which affects quality of life. The presence of wearing off affects also the 
quality of life of these patients.
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OBJECTIVES: Benzodiazepines and Z-drugs are extensively prescribed in patients 
with insomnia, and their use raises public health concerns of dependence and increased 
indirect costs (e.g., falls). The aim of this study was to investigate prescribing practice 
patterns of Prolonged-Release Melatonin (PRM), a newly licensed hypnotic, in real-life 
settings using longitudinal prescription database analyses. METHODS: Longitudinal 
data of patients initiating PRM was extracted from a primary care prescription data-
base in Germany (IMS-DA). Patient characteristics (age, gender) and treatment infor-
mation (drug name, prescription date, number of packages and indication) were 
retrieved. Descriptive analyses investigated the proportion of patients with or without 
a past history of hypnotic use (deﬁned as at least one benzodiazepine or Z-drug (BZD-
Z) prescription within 3 months prior to PRM initiation). Descriptive statistics identi-
ﬁed the proportion of patients with or without BZD-Z prescriptions within the 3 
months following treatment initiation. Sensitivity analyses were performed on longer 
follow-up periods (6 months) and higher numbers of previous BZD-Z prescriptions 
(at least 2) to test the robustness of the ﬁndings. RESULTS: 1,382 eligible patient 
records were retrieved. Two-thirds were female (mean age 62). Among them, 512 
patients had a minimum 3-month history and 3-month follow-up. Approximately 
80% were not prescribed BZD-Z before PRM initiation and of those, 90% were still 
not prescribed any BZD-Z after 3 months. Among previous BZD-Z users, results 
showed that approximately 1/3 (36/112) were not prescribed any BZD-Z medication 
3 months after PRM initiation. Results were substantiated by sensitivity analyses on 
both longer follow-up duration and a greater number of previous BZD-Z prescrip-
tions. CONCLUSIONS: PRM might represent an interesting alternative to BZD-Z use 
for the treatment of insomnia. Further research with a larger study population is 
needed to conﬁrm these results.
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BACKGROUND: Chronic inﬂammatory demyelinating polyradiculoneuropathy 
(CIDP) is an acquired immune-mediated inﬂammatory disorder that targets the myelin 
sheaths of the peripheral nervous system. Intravenous immunoglobulin (IVIg) is a 
blood product containing immunoglobulin G (IgG) that has been pooled from many 
human donors. In the fall of 2008 CIDP became an approved indication for IVIg in 
both Canada and the United States. OBJECTIVES: To evaluate the clinical effective-
ness and safety of IVIg for the treatment of CIDP through a systematic review of the 
literature. METHODS: The Medline (1950–2009; In-Process & Other Non-Indexed 
Citations) and EMBASE (1980–2009) databases were searched through the Ovid 
interface. A methodological ﬁlter was applied to limit retrieval to clinical trials, MAs, 
or SRs. Retrieval was limited to humans and no language restrictions were employed. 
Extracted data were pooled to estimate the effect size of IVIg treatment based on the 
random-effects model. RESULTS: Nine unique RCTs were identiﬁed. Three of the 
nine trials compared IVIg therapy to an active comparator (plasma exchange (PE), PE 
using extracorporeal immunoadsorption, or oral prednisolone), and the other six trials 
were placebo-controlled. There was no incremental beneﬁt seen in the primary out-
comes when comparing IVIg therapy and the active comparator. Five of the six 
placebo-controlled trials showed IVIg therapy to be superior to placebo based upon 
a variety of disability or impairment outcomes. CONCLUSIONS: IVIg therapy is sta-
tistically superior to placebo treatment in reducing the disability and impairment for 
CIDP patients. IVIg demonstrates similar effectiveness as the alternative treatment 
strategies of PE and methyprednisolone.
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OBJECTIVES: In Canada, public drug plans provide limited reimbursement for 
Alzheimer’s disease (AD) medications. For most Canadians, the cost of these medica-
tions is paid ‘out-of-pocket’. This study was conducted to assess the Canadian general 
public’s willingness-to-pay (WTP) for unrestricted access to AD medications. 
METHODS: Five-hundred participants (age q18 years) were recruited nationally and 
stratiﬁed by income. Data were collected via computer-assisted telephone interviews. 
Participants were presented with four ‘efﬁcacy’ scenarios describing a hypothetical, 
new AD medication. In two scenarios, the medication was described as modifying the 
symptoms of cognitive decline. In the other two scenarios, the medication was 
described as halting disease progression. For each pair of ‘efﬁcacy’ scenarios, the 
medication was assumed to have no adverse effects in one scenario and a 30% chance 
of adverse effects in the other scenario. For every scenario, participants were asked 
whether they would support unrestricted access to the medication through an annual 
increase in personal income taxes. Participants then provided the maximum tax 
increase that they would support. WTP was elicited using a bid range: $75, $150, or 
$225. Open-ended questions allowed participants to specify values outside the range. 
Participants were randomized to order of scenarios and bids. Differences between 
scenarios were assessed using Bowker’s test of symmetry. RESULTS: Overall, 80% of 
participants (n  398) supported a tax increase under at least one scenario. Maximum 
WTP did not differ across scenarios (median  $150, interquartile range  $75 to $225 
[for all four scenarios]). After categorization ($75, $75, $150, $225,  $225), the 
distribution of maximum WTP did not differ by efﬁcacy (symptom modiﬁcation versus 
halting disease progression [p  0.34]) or adverse effects (30% chance versus none 
[p  0.54]). CONCLUSIONS: Most participants reported support for a tax increase. 
Once the decision was made to support an increase, maximum WTP was unaffected 
by efﬁcacy or the potential for adverse effects.
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OBJECTIVES: In Canada, the cost of Alzheimer’s disease (AD) medications is mainly 
borne by patients and caregivers. The primary objective of this study was to measure 
the Canadian general public’s support for a program of unrestricted access to AD 
medications. The secondary objective was to identify determinants of support for the 
program. METHODS: A national sample of 500 Canadians, aged 18 years or older, 
was randomly recruited to participate in a computer-assisted telephone interview. The 
sample was stratiﬁed by income. Participants were presented with a set of randomly-
ordered scenarios describing a hypothetical, new AD medication. The efﬁcacy of the 
medication was varied by scenario: the medication was alternately described as modi-
fying the symptoms of cognitive decline or actually halting disease progression. The 
adverse effects proﬁle was also varied in the scenarios: no adverse effects or a 30% 
chance of some adverse effects. For each scenario, participants were asked whether 
they supported an annual increase in personal income taxes to fund unrestricted access 
to the AD medication. Logistic regression was conducted to identify factors that might 
explain support for the tax increase. RESULTS: Percentage of respondents supporting 
a tax increase varied with scenario: symptom modiﬁcation and 30% chance of adverse 
effects  49% (n  244); symptom modiﬁcation, no adverse effects  58% (n  290); 
halt progression and 30% chance of adverse effects  54% (n  270); halt progression, 
no adverse effects  67% (n  333). Relative to the ‘symptom treatment and 30% 
chance of adverse effects’ scenario, the level of support was different (p  0.05) for 
all except the ‘halt progression and 30% chance of adverse effects’ scenario (p  0.15). 
No determinant (e.g., age, sex) could consistently explain support across all four 
 scenarios. CONCLUSIONS: Support for the tax increase varied by the efﬁcacy and 
